US 11,857,533 B2
Composition for preventing or treating obesity or lipid-related metabolic disorders
Jung Taek Seo, Seoul (KR); Seok Jun Moon, Seoul (KR); and Sung-Jin Kim, Seoul (KR)
Assigned to Nexyon Biotech Co., Ltd., Seoul (KR)
Appl. No. 17/055,058
Filed by Nexyon Biotech Co., Ltd., Seoul (KR)
PCT Filed Mar. 2, 2020, PCT No. PCT/KR2020/002958
§ 371(c)(1), (2) Date Nov. 12, 2020,
PCT Pub. No. WO2020/184884, PCT Pub. Date Sep. 17, 2020.
Claims priority of application No. 10-2019-0028547 (KR), filed on Mar. 13, 2019.
Prior Publication US 2021/0393581 A1, Dec. 23, 2021
Int. Cl. A61K 31/37 (2006.01); A61P 1/16 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61K 31/404 (2006.01); A61K 31/473 (2006.01); A61K 31/5377 (2006.01); A61K 31/56 (2006.01); A61K 31/568 (2006.01); A61K 31/5685 (2006.01); A61K 31/662 (2006.01)
CPC A61K 31/37 (2013.01) [A61K 31/404 (2013.01); A61K 31/473 (2013.01); A61K 31/5377 (2013.01); A61K 31/56 (2013.01); A61K 31/568 (2013.01); A61K 31/5685 (2013.01); A61K 31/662 (2013.01); A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01)] 4 Claims
 
1. A method for ameliorating or treating obesity,
comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising irosustat to a subject.